Literature DB >> 33217769

Factors Associated With Hepatitis A Mortality During Person-to-Person Outbreaks: A Matched Case-Control Study-United States, 2016-2019.

Megan G Hofmeister1, Jian Xing1, Monique A Foster1, Ryan J Augustine1, Cole Burkholder2, Jim Collins2, Shannon McBee3, Erica D Thomasson3,4, Douglas Thoroughman4,5, Mark K Weng1, Philip R Spradling1.   

Abstract

BACKGROUND AND AIMS: During 2016-2020, the United States experienced person-to-person hepatitis A outbreaks that are unprecedented in the vaccine era, during which case-fatality ratios reported by some jurisdictions exceeded those historically associated with hepatitis A. APPROACH AND
RESULTS: To identify factors associated with hepatitis A-related mortality, we performed a matched case-control study (matched on age [±5 years] and county of residence in a 1:4 ratio) using data collected from health department and hospital medical records of outbreak-associated patients in Kentucky, Michigan, and West Virginia. Controls were hepatitis A outbreak-associated patients who did not die. There were 110 cases (mean age 53.6 years) and 414 matched controls (mean age 51.9 years); most cases (68.2%) and controls (63.8%) were male. Significantly (P < 0.05) higher odds of mortality were associated with preexisting nonviral liver disease (adjusted odds ratio [aOR], 5.2), history of hepatitis B (aOR, 2.4), diabetes (aOR, 2.2), and cardiovascular disease (aOR, 2.2), as well as initial Model for End-Stage Liver Disease (MELD) score ≥ 30 (aOR, 10.0), aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio > 2 (aOR, 10.3), and platelet count < 150,000/μL (aOR, 3.7) among hepatitis A outbreak-associated patients in the independent multivariable conditional logistic regression analyses (each model adjusted for sex).
CONCLUSIONS: Preexisting liver disease, diabetes, cardiovascular disease, and initial MELD score ≥ 30, AST/ALT ratio ≥ 1, and platelet count < 150,000/μL among hepatitis A patients were independently associated with higher odds of mortality. Providers should be vigilant for such features and have a low threshold to escalate care and consider consultation for liver transplantation. Our findings support the recommendation of the Advisory Committee on Immunization Practices to vaccinate persons with chronic liver disease, though future recommendations to include adults with diabetes and cardiovascular disease should be considered.
© 2020 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33217769     DOI: 10.1002/hep.31645

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  5 in total

1.  The ZCCHC14/TENT4 complex is required for hepatitis A virus RNA synthesis.

Authors:  You Li; Ichiro Misumi; Tomoyuki Shiota; Lu Sun; Erik M Lenarcic; Hyejeong Kim; Takayoshi Shirasaki; Adriana Hertel-Wulff; Taylor Tibbs; Joseph E Mitchell; Kevin L McKnight; Craig E Cameron; Nathaniel J Moorman; David R McGivern; John M Cullen; Jason K Whitmire; Stanley M Lemon
Journal:  Proc Natl Acad Sci U S A       Date:  2022-07-07       Impact factor: 12.779

2.  Amantadine and Rimantadine Inhibit Hepatitis A Virus Replication through the Induction of Autophagy.

Authors:  Reina Sasaki-Tanaka; Toshikatsu Shibata; Mitsuhiko Moriyama; Hiroaki Okamoto; Hirofumi Kogure; Tatsuo Kanda
Journal:  J Virol       Date:  2022-08-30       Impact factor: 6.549

3.  The AST/ALT Ratio (De Ritis Ratio) Represents an Unfavorable Prognosis in Patients in Early-Stage SFTS: An Observational Cohort Study.

Authors:  Lianzi Wang; Yang Xu; Shubing Zhang; Asma Bibi; Yuanhong Xu; Tao Li
Journal:  Front Cell Infect Microbiol       Date:  2022-02-08       Impact factor: 5.293

4.  Favipiravir Inhibits Hepatitis A Virus Infection in Human Hepatocytes.

Authors:  Reina Sasaki-Tanaka; Toshikatsu Shibata; Hiroaki Okamoto; Mitsuhiko Moriyama; Tatsuo Kanda
Journal:  Int J Mol Sci       Date:  2022-02-27       Impact factor: 5.923

Review 5.  Hepatitis A: Epidemiology, High-Risk Groups, Prevention and Research on Antiviral Treatment.

Authors:  Marion Migueres; Sébastien Lhomme; Jacques Izopet
Journal:  Viruses       Date:  2021-09-22       Impact factor: 5.048

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.